AR044452A1 - Combinacion de un antagonista del receptor p2x7 y un inhibidor del factor de necrosis tumoral alfa - Google Patents

Combinacion de un antagonista del receptor p2x7 y un inhibidor del factor de necrosis tumoral alfa

Info

Publication number
AR044452A1
AR044452A1 ARP040101848A ARP040101848A AR044452A1 AR 044452 A1 AR044452 A1 AR 044452A1 AR P040101848 A ARP040101848 A AR P040101848A AR P040101848 A ARP040101848 A AR P040101848A AR 044452 A1 AR044452 A1 AR 044452A1
Authority
AR
Argentina
Prior art keywords
necrosis factor
tumor necrosis
alfa
combination
factor inhibitor
Prior art date
Application number
ARP040101848A
Other languages
English (en)
Inventor
Nigel Boughton-Smith
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0312321A external-priority patent/GB0312321D0/en
Priority claimed from SE0301655A external-priority patent/SE0301655D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR044452A1 publication Critical patent/AR044452A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un producto farmacéutico o conjunto de elementos (kit) que comprende un primer ingrediente activo que es un antagonista del receptor P2X7 y dicho antagonista del receptor P2X7 es un derivado de adamantilo y un segundo ingrediente activo que es un inhibidor del factor de necrosis tumoral alfa (etanercept, infliximab, adalimumab, entre otros), para su utilización en el tratamiento de trastornos inflamatorios.
ARP040101848A 2003-05-29 2004-05-28 Combinacion de un antagonista del receptor p2x7 y un inhibidor del factor de necrosis tumoral alfa AR044452A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0312321A GB0312321D0 (en) 2003-05-29 2003-05-29 New combination
SE0301655A SE0301655D0 (sv) 2003-06-05 2003-06-05 New combination

Publications (1)

Publication Number Publication Date
AR044452A1 true AR044452A1 (es) 2005-09-14

Family

ID=33492248

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101848A AR044452A1 (es) 2003-05-29 2004-05-28 Combinacion de un antagonista del receptor p2x7 y un inhibidor del factor de necrosis tumoral alfa

Country Status (15)

Country Link
US (1) US20070032465A1 (es)
EP (1) EP1633401A1 (es)
JP (1) JP2007501270A (es)
KR (1) KR20060037258A (es)
AR (1) AR044452A1 (es)
BR (1) BRPI0410739A (es)
CA (1) CA2526883A1 (es)
CO (1) CO5640094A2 (es)
IS (1) IS8188A (es)
MX (1) MXPA05012705A (es)
NO (1) NO20056131L (es)
RU (1) RU2350354C2 (es)
TW (1) TW200507829A (es)
UY (1) UY28335A1 (es)
WO (1) WO2004105798A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300480D0 (sv) 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
US20070281931A1 (en) * 2003-05-29 2007-12-06 Nigel Boughton-Smith Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate
US20070010497A1 (en) * 2003-05-29 2007-01-11 Nigel Boughton-Smith Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
US20090042832A1 (en) * 2005-03-07 2009-02-12 Ganga Raju Gokaraju Novel salts of boswellic acids and selectively enriched boswellic acids and processes for the same
GB0919594D0 (en) 2009-11-09 2009-12-23 Glaxo Group Ltd Compounds
US20130195919A1 (en) 2010-03-05 2013-08-01 President And Fellows Of Harvard College Induced dendritic cell compositions and uses thereof
US9538710B2 (en) 2010-04-01 2017-01-10 Tony Wayne Covely Crop product tracking system and method
US10444122B2 (en) 2010-04-01 2019-10-15 Agri-Labs Holdings Llc Soil sample tracking system and method
EP2739281A1 (en) * 2011-08-04 2014-06-11 The U.S.A. as represented by the Secretary, Department of Health and Human Services Treatment and prevention of diseases mediated by microorganisms via drug-mediated manipulation of the eicosanoid balance
MY188825A (en) 2012-05-18 2022-01-06 Genentech Inc High-concentration monoclonal antibody formulations
KR102035463B1 (ko) * 2018-02-14 2019-11-26 연세대학교 산학협력단 암 줄기세포의 치료용 약학 조성물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471491A (en) * 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) * 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
US4349552A (en) * 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
US4751292A (en) * 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
US5399564A (en) * 1991-09-03 1995-03-21 Dowelanco N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or aralkylamino) pyridine pesticides
AU722472B2 (en) * 1996-05-20 2000-08-03 Darwin Discovery Limited Quinoline carboxamides as TNF inhibitors and as PDE-IV inhibitors
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
BR0009651A (pt) * 1999-04-09 2002-01-08 Astrazeneca Ab Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para tratar artrite reumatóide e uma doença obstrutiva das vias aéreas
SE9904505D0 (sv) * 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) * 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
GB0013737D0 (en) * 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
SK286759B6 (sk) * 2001-07-02 2009-05-07 N.V. Organon Tetrahydrochinolínové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
PA8557501A1 (es) * 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
WO2003042190A1 (en) * 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
SE0103836D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
US6908939B2 (en) * 2001-12-21 2005-06-21 Galderma Research & Development S.N.C. Biaromatic ligand activators of PPARγ receptors
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300445D0 (sv) * 2003-02-18 2003-02-18 Astrazeneca Ab New combination
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
US20070281931A1 (en) * 2003-05-29 2007-12-06 Nigel Boughton-Smith Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate
US20070010497A1 (en) * 2003-05-29 2007-01-11 Nigel Boughton-Smith Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination

Also Published As

Publication number Publication date
RU2350354C2 (ru) 2009-03-27
TW200507829A (en) 2005-03-01
BRPI0410739A (pt) 2006-06-27
US20070032465A1 (en) 2007-02-08
MXPA05012705A (es) 2006-02-08
IS8188A (is) 2005-12-20
CA2526883A1 (en) 2004-12-09
AU2004243137A1 (en) 2004-12-09
KR20060037258A (ko) 2006-05-03
NO20056131L (no) 2006-02-28
WO2004105798A1 (en) 2004-12-09
RU2005136131A (ru) 2006-07-27
CO5640094A2 (es) 2006-05-31
JP2007501270A (ja) 2007-01-25
UY28335A1 (es) 2004-12-31
EP1633401A1 (en) 2006-03-15

Similar Documents

Publication Publication Date Title
AR044452A1 (es) Combinacion de un antagonista del receptor p2x7 y un inhibidor del factor de necrosis tumoral alfa
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
CL2003002353A1 (es) Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
DE602006004844D1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
NO20072558L (no) Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
NO20071446L (no) Endotelin A reseptor (ETA)-antagonister i kombinasjon med fosfodiesterase 5-inhibitorer (PDE5) og anvendelser derav.
TW200612919A (en) Lonidamine analogues and their use in male contraception and cancer treatment
ATE423114T1 (de) Aminocyclopropancarbonsäureamidderivate als bradykininantagonisten
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
WO2006002057A3 (en) Treatment of acne
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
AR058173A1 (es) Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas
UY28517A1 (es) Nueva combinación
ATE426409T1 (de) Antitumor-kombinationen mit vegf-trap und 5fu oder einem seiner derivate
DE602006013792D1 (de) Pharmazeutische zusammensetzungen mit nep-inhibitoren, inhibitoren des endogenes endothelin produzierenden systems und diuretika
UY28007A1 (es) Tratamiento terapeutico
AR056517A1 (es) Composiciones y metodos farmaceuticos utilizando temozolomida y un inhibidor de la proteina quinasa
EA200970353A1 (ru) Комбинированное лекарственное средство
BRPI0409475A (pt) inibição de vav na rejeição de enxerto
RS52069B (en) NEW THERAPEUTIC USE OF ADRENERGIC ALFUZOSIN

Legal Events

Date Code Title Description
FB Suspension of granting procedure